| Point-of-care CAR T-cell production (ARI-0001) using a closed semi-automatic bioreactor: experience from an academic phase I clinical trial M Castella, M Caballero-Baños, V Ortiz-Maldonado, ... Frontiers in immunology 11, 482, 2020 | 120 | 2020 |
| CART19-BE-01: a multicenter trial of ARI-0001 cell therapy in patients with CD19+ relapsed/refractory malignancies V Ortíz-Maldonado, S Rives, M Castellà, A Alonso-Saladrigues, ... Molecular Therapy 29 (2), 636-644, 2021 | 115 | 2021 |
| Development of a novel anti-CD19 chimeric antigen receptor: a paradigm for an affordable CAR T cell production at academic institutions M Castella, A Boronat, R Martín-Ibáñez, V Rodríguez, G Suñé, ... Molecular Therapy-Methods & Clinical Development 12, 134-144, 2019 | 111 | 2019 |
| Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: a position paper I Los-Arcos, G Iacoboni, M Aguilar-Guisado, L Alsina-Manrique, ... Infection 49, 215-231, 2021 | 110 | 2021 |
| Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow … AM Spanjaart, P Ljungman, R de La Camara, G Tridello, ... Leukemia 35 (12), 3585-3588, 2021 | 100 | 2021 |
| Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma M Kwon, G Iacoboni, JL Reguera, LL Corral, RH Morales, ... Haematologica 108 (1), 110, 2023 | 84 | 2023 |
| Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy N Gazeau, EC Liang, JM Voutsinas, P Barba, G Iacoboni, M Kwon, ... Transplantation and cellular therapy 29 (7), 430-437, 2023 | 42 | 2023 |
| Epigenetic profiling and response to CD19 chimeric antigen receptor T-cell therapy in B-cell malignancies CA Garcia-Prieto, L Villanueva, A Bueno-Costa, V Davalos, ... JNCI: Journal of the National Cancer Institute 114 (3), 436-445, 2022 | 37 | 2022 |
| Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter’s transformation V Ortiz-Maldonado, G Frigola, M Español-Rego, O Balagué, ... Frontiers in Oncology 12, 828471, 2022 | 29 | 2022 |
| First report of CART treatment in AL amyloidosis and relapsed/refractory multiple myeloma A Oliver-Caldes, R Jiménez, M Español-Rego, MT Cibeira, ... Journal for Immunotherapy of Cancer 9 (12), 2021 | 29 | 2021 |
| Best treatment option for patients with refractory aggressive B-cell lymphoma in the CAR-T cell era: real-world evidence from GELTAMO/GETH Spanish groups M Bastos-Oreiro, A Gutierrez, JL Reguera, G Iacoboni, L López-Corral, ... Frontiers in immunology 13, 855730, 2022 | 27 | 2022 |
| The biology behind PI3K inhibition in chronic lymphocytic leukaemia V Ortiz-Maldonado, M García-Morillo, J Delgado Therapeutic advances in hematology 6 (1), 25-36, 2015 | 24 | 2015 |
| CD34+CD19−CD22+ B-cell progenitors may underlie phenotypic escape in patients treated with CD19-directed therapies C Bueno, S Barrera, A Bataller, V Ortiz-Maldonado, N Elliot, S O’Byrne, ... Blood, The Journal of the American Society of Hematology 140 (1), 38-44, 2022 | 22 | 2022 |
| Factors associated with the clinical outcome of patients with relapsed/refractory CD19+ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy V Ortiz-Maldonado, S Rives, M Español-Rego, A Alonso-Saladrigues, ... Journal for immunotherapy of cancer 9 (12), 2021 | 21 | 2021 |
| Lymphodepletion–an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle B Lickefett, L Chu, V Ortiz-Maldonado, L Warmuth, P Barba, M Doglio, ... Frontiers in Immunology 14, 1303935, 2023 | 20 | 2023 |
| Manufacturing and management of CAR T-cell therapy in “COVID-19’s time”: central versus point of care proposals I Ortiz de Landazuri, N Egri, G Muñoz-Sánchez, V Ortiz-Maldonado, ... Frontiers in Immunology 11, 573179, 2020 | 17 | 2020 |
| Safety and efficacy of two anakinra dose regimens for refractory CRS or ICANS after CAR T-cell therapy N Gazeau, P Barba, G Iacoboni, M Kwon, R Bailen, JL Reguera, LL Corral, ... Blood 138, 2816, 2021 | 16 | 2021 |
| CAR-T after stem cell transplantation in B-cell lymphoproliferative disorders: are they really autologous or allogenic cell therapies? A Bartoló-Ibars, M Uribe-Herranz, G Muñoz-Sánchez, C Arnaldos-Pérez, ... Cancers 13 (18), 4664, 2021 | 16 | 2021 |
| Practical aspects of chimeric antigen receptor T-cell administration: From commercial to point-of-care manufacturing N Martinez-Cibrian, M Español-Rego, M Pascal, J Delgado, ... Frontiers in Immunology 13, 1005457, 2022 | 15 | 2022 |
| Is there a role for minimal residual disease monitoring in the management of patients with hairy‐cell leukaemia? V Ortiz‐Maldonado, N Villamor, T Baumann, M Aymerich, L Magnano, ... British Journal of Haematology 183 (1), 2018 | 11 | 2018 |
